Her -2 over–expression in gastric carcinoma in Lagos: a 5 years retrospective study

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter V. Onyekwelu
Citation Annals of Oncology (2016) 27 (2): 86-101. 10.1093/annonc/mdw201
Authors V. Onyekwelu1, K. Badmos2, N. Awolola2, F. Abdulkareem2
  • 1Me Cure Healthcare Limited, Lagos, Nigeria, /
  • 2Lagos University Teaching Hospital, Lagos, Nigeria, /


Gastric carcinoma is the second most common digestive tract cancer and the third leading cause of cancer-related death worldwide. In Nigeria, it is a major contributor to cancer-related mortality. There is a recent interest in studying the benefits of targeted therapy in its management using anti-HER-2 monoclonal antibody because of the increased overall survival when used in combination with chemotherapy.


The objective of this study was to determine the frequency of HER-2 over-expression in gastric carcinomas in Lagos, comparing it with known pathologic and prognostic factors and also with similar available studies.